Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia - Hehlmann, Rüdiger; Lauseker, Michael; Jung-Munkwitz, Susanne; Leitner, Armin; Müller, Martin C.; Pletsch, Nadine; Proetel, Ulrike; Haferlach, Claudia; Schlegelberger, Brigitte; Balleisen, Leopold; Hänel, Mathias; Pfirrmann, Markus; et al. (Journal of clinical oncology, 2011)
Keywords: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Benzamides; Biological and medical sciences; Chi-Square Distribution; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Germany; Hematologic and hematopoietic diseases; Humans; Imatinib Mesylate; Interferon-alpha - administration & dosage; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; Piperazines - administration & dosage; Protein Kinase Inhibitors - administration & dosage; Pyrimidines - administration & dosage; Remission Induction; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome; Tumors; Young Adult; Germany; Antineoplastic agent; Imatinib; Enzyme; Tyrosine kinase inhibitor; Alpha interferon; Transferases; Enzyme inhibitor; Chronic myelogenous leukemia; Early stage; Malignant hemopathy; Myeloproliferative syndrome; Cancerology; Protein-tyrosine kinase; Comparative study; Cancer